Iron chelation therapy
- 25 December 2000
- journal article
- research article
- Published by Wiley in Reviews in Clinical and Experimental Hematology
- Vol. 4 (4) , 337-361
- https://doi.org/10.1046/j.1468-0734.2000.00024.x
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- The Hexadentate Hydroxypyridinonate TREN‐(Me‐3,2‐HOPO) is a More Orally Active Iron Chelator Than Its Bidentate AnalogueJournal of Pharmaceutical Sciences, 2000
- Iron Deposition in the Anterior Pituitary in Homozygous Beta-Thalassemia: MRI Evaluation and Correlation with Gonadal FunctionJournal of Pediatric Endocrinology and Metabolism, 2000
- DeferiproneDrugs, 1999
- Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia MajorNew England Journal of Medicine, 1994
- Design, Properties, and Effective Use of the Oral Chelator L1 and OtherAnnals of the New York Academy of Sciences, 1990
- L1 (1,2‐dimethyl‐3‐hydroxypyrid‐4‐one) for oral iron chelation in patients with beta‐thalassaemia majorBritish Journal of Haematology, 1990
- Yersinia Sepsis in Patients with Iron Overload Treated with DeferoxamineNew England Journal of Medicine, 1986
- Visual and Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine InfusionsNew England Journal of Medicine, 1986
- Magnetic-Susceptibility Measurement of Human Iron StoresNew England Journal of Medicine, 1982
- Pyridoxal complexes as potential chelating agents for oral therapy in transfusional iron overloadJournal of Pharmacy and Pharmacology, 1982